Objective: To reassess the relative potencies of teicoplanin and vancomycin following several years of clinical usage. Methods: The glycopeptide susceptibilities of clinical isolates of staphylococci collected from 70 hospitals in 1995 were determined using NCCLS (National Committee for Clinical Laboratory Standards) methods. Results: In total, 2885 isolates of Staphylococcus aureus and 1480 isolates of coagulase-negative staphylococci were collected. S. aureus was significantly less susceptible to vancomycin (MIC50 1 mg/L) than teicoplanin (MIC50 0.5 mg/L), but the reverse was the case for S. haemolyticus and S. epidermidis. No S. aureus isolate was resistant (≥ 32 mg/L) to either glycopeptide, but nine isolates of coagulase-negative staphylococci had an MIC of teicoplanin of 32 mg/L. Respiratory isolates of S. aureus were less susceptible to glycopeptides than those from other sites. Staphylococci from Belgium and Italy were less susceptible to teicoplanin than isolates from other countries. Conclusions: This European survey shows that in 10 years of clinical use there have been no major changes in the susceptibility of staphylococci to the glycopeptides.
|Number of pages||7|
|Journal||Clinical Microbiology and Infection|
|Publication status||Published - Sep 1999|
- Staphylococcus spp.
ASJC Scopus subject areas
- Microbiology (medical)